Stanford University Completes Patient Enrollment in Phase 1 Clinical Trial of Bispecific CAR-T Therapy Targeting CD19/CD22 for Pediatric Leukemia
Clinical Need for CD19/CD22 Bispecific Therapy
Existing approved CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapies, such as Novartis' (NVS) Kymriah (tisagenlecleucel), have demonstrated excellent efficacy. However, recurrence due to antigen escape, where CD19 protein is lost, remains a persistent problem. Researchers at Stanford University have designed a bispecific CAR-T cell therapy that simultaneously targets CD19 and CD22 proteins to address this challenge. This strategy aims to enhance treatment durability by attacking cancer cells with a different antigen if one antigen is masked. The success of this bispecific platform in pediatric and adolescent patients with poor prognoses could represent a significant turning point in improving the potential for cure.
Design and Combination Therapy in the Stanford Phase 1 Trial
The Phase 1 clinical trial (NCT03241940), which has now completed patient enrollment, involved 33 pediatric and adolescent patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Prior to CAR-T cell infusion, patients received a combination chemotherapy regimen of fludarabine phosphate and cyclophosphamide to improve the tumor microenvironment and enhance cell activity. This phase primarily focuses on dose escalation to determine the maximum tolerated dose (MTD) while minimizing adverse effects and establishing a robust manufacturing process. Establishing a successful manufacturing rate is a critical technical indicator for future commercial scale-up.
Unmet Needs in the Pediatric Leukemia Market and Competitive Landscape
The pediatric R/R B-ALL field represents an area of extreme unmet need within the global acute lymphoblastic leukemia therapeutics market, which is expected to reach approximately $4.62 billion to $5.59 billion in 2026. Currently, Kymriah dominates the pediatric leukemia market, but recurrence rates are significant. It faces competition from other targeted therapies such as Amgen's (AMGN) Blincyto (blinatumomab) and Pfizer's (PFE) Besponsa. In this landscape, bispecific CAR-T therapy is expected to overcome the limitations of existing single-target therapies and open a new horizon for the standard of care. In the long term, this therapy may serve as a final salvage therapy for patients who have failed high-cost single-target treatments.
Commercialization of Academic Clinical Trials and Investment Perspective
This study is a non-listed clinical trial led by the Stanford Cancer Institute, but the research results have already been licensed to companies such as CARGO Therapeutics (CRGX), a Nasdaq-listed company, and have attracted significant venture capital funding. Although CARGO has discontinued its CD22 single-target pipeline (CRG-022) due to safety concerns and shifted to the development of a trispecific CAR-T (CRG-023), the basic research data on bispecific therapy serves as a key compass in designing optimal combinations. Therefore, investors should comprehensively review the long-term safety and efficacy data from this trial to accurately capture the technological trends and commercial value in the cell therapy market.
This Phase 1 clinical trial (NCT03241940) validates the efficacy of developing a next-generation immunotherapy that simultaneously targets CD19 and CD22 to address the major challenge in CAR-T therapy since the approval of Novartis' (NVS) Kymriah: recurrence due to CD19 antigen escape. With the global acute lymphoblastic leukemia (ALL) market expected to grow rapidly from approximately $4.62 billion to $5.59 billion in 2026 to a maximum of $11.8 billion in 2035, bispecific therapies represent a key pipeline with the potential to achieve higher cure rates compared to existing CD19 single-target CAR-T therapies and Amgen's (AMGN) Blincyto. The research results from this trial have been transferred to CARGO Therapeutics (CRGX), a Nasdaq-listed company, and are being used as foundational data to reshape the commercial landscape of the next-generation cell therapy market. In the short term, securing safety data in pediatric and adolescent patients is critical, but in the medium to long term, the bispecific platform's potential for standard of care (SoC) adoption and improved cure rates through antigen escape inhibition make it a key indicator for biotech sector investors.
Source: ClinicalTrials.gov (api_ct)